The recommended screening test for prostate cancer: prostate specific antigen (PSA) is mired in controversy surrounding its benefits and its ability to guide appropriate treatment options for patients with newly-diagnosed, localized prostate cancer. This evidence concerns the gene KLK3 and prostate carcinoma.